
    
      This is a multinational, double-blind, two-arm, parallel, randomized, Phase 3 study
      evaluating the efficacy and safety of TAS-102 plus BSC versus placebo plus BSC in patients
      with metastatic gastric cancer who have previously received at least 2 prior regimens for
      advanced disease. Eligible patients will be centrally randomized (2:1) to TAS-102 + BSC
      (experimental arm) or placebo + BSC (control arm).
    
  